The US Food and Drug Administration (FDA) has approved the second human trial of human embryonic stem cells — this one testing cells in people with a progressive form of blindness, the company said yesterday.
Worcester, Massachusetts-based Advanced Cell Technology (ACT) said it would start testing its stem cell-based treatment on 12 patients with Stargardt’s macular dystrophy.
SECOND APPROVAL
It is the second trial of human embryonic stem cells to be approved by the FDA this year.
Last month, Geron Corp enrolled the first patient in its study using the cells in people whose spinal cords have been crushed.
GAMBLE
“It is exciting — a vindication. All this work really came through,” said Robert Lanza, chief medical officer of the company, which has struggled to stay solvent as it gambled on the controversial cells.
Stem cells are the body’s master cells, the source of all other cells.
Proponents of using embryonic stem cells say the field could transform medicine, providing treatments for brain diseases like Parkinson’s, juvenile diabetes or severe injuries.
However, opponents object because to get the cells, someone has to take apart a human embryo.
CHANGE
Last year, the administration of US President Barack Obama overturned the strictest of the limitations on using federal funds for the research, but this summer, two researchers challenged the policy.
A US appeals court has ruled that funding could continue while the government appeals, but grants from the US National Institutes of Health have been frozen and unfrozen as various courts have weighed in.
STARGARDT’S DISEASE
Stargardt’s disease causes progressive vision loss, usually starting in children or young adults 10 to 20 years old, as eye tissue called the retinal pigment epithelium, or RPE, degenerates.
There is currently no treatment for Stargardt’s disease.
ACT has coaxed human embryonic stem cells into becoming RPE cells, which will be infused into patients’ eyes.
BOUNTIFUL SUPPLY
“We can generate a virtually unlimited supply of healthy RPE cells,” Lanza said.
The company uses a unique type of human embryonic stem cell, taken from embryos left over at fertility clinics.
A single cell is removed when the embryo only has about eight cells — a process sometimes used when clinics want to test the embryos of people with genetic diseases to ensure that they are healthy.
CONTROVERSY
In theory, the embryo can continue developing, but in this case ACT has not implanted the embryo.
In the past, the company hoped this method of generating human embryonic stem cells would be less controversial than using an entire embryo.
Lanza said getting FDA approval for the trial was difficult.
“They had us jumping through hoops,” he said.
This was in part because the powerful embryonic cells have the power to give rise to all cell types and can cause teratomas — strange tumors containing a mix of cells.
ONE CELL ONLY
Lanza said the company can find even a single cell that might do this and remove it from the treatment batch.
In addition, he said treating an eye disease offers the opportunity to watch the treatment.
“We can look into the eye in real time and see what is going on,” he said.
APPROVAL PENDING
Research centers at the University of Oregon and University of Massachusetts will begin enrolling patients after their internal Institutional Review Boards approve the trial.
“My guess is that we could start in as soon as two to three months,” Lanza said.
Taiwan Transport and Storage Corp (TTS, 台灣通運倉儲) yesterday unveiled its first electric tractor unit — manufactured by Volvo Trucks — in a ceremony in Taipei, and said the unit would soon be used to transport cement produced by Taiwan Cement Corp (TCC, 台灣水泥). Both TTS and TCC belong to TCC International Holdings Ltd (台泥國際集團). With the electric tractor unit, the Taipei-based cement firm would become the first in Taiwan to use electric vehicles to transport construction materials. TTS chairman Koo Kung-yi (辜公怡), Volvo Trucks vice president of sales and marketing Johan Selven, TCC president Roman Cheng (程耀輝) and Taikoo Motors Group
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
RECORD-BREAKING: TSMC’s net profit last quarter beat market expectations by expanding 8.9% and it was the best first-quarter profit in the chipmaker’s history Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), which counts Nvidia Corp as a key customer, yesterday said that artificial intelligence (AI) server chip revenue is set to more than double this year from last year amid rising demand. The chipmaker expects the growth momentum to continue in the next five years with an annual compound growth rate of 50 percent, TSMC chief executive officer C.C. Wei (魏哲家) told investors yesterday. By 2028, AI chips’ contribution to revenue would climb to about 20 percent from a percentage in the low teens, Wei said. “Almost all the AI innovators are working with TSMC to address the
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”